Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization.

Duplications and deletions are known to cause a number of genetic disorders, yet technical difficulties and financial considerations mean that screening for these mutations, especially duplications, is often not performed. We have adapted multiplex amplifiable probe hybridization (MAPH) for the screening of the DMD gene, mutations in which cause Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy. MAPH involves the quantitative recovery of specifically designed probes following hybridization to immobilized genomic DNA. We have engineered probes for each of the 79 exons of the DMD gene, and we analyzed them by using a 96-capillary sequencer. We screened 24 control individuals, 102 patients, and 23 potential carriers and detected a large number of novel rearrangements, especially small, one- and two-exon duplications. A duplication of exon 2 alone was the most frequently occurring mutation identified. Our analysis indicates that duplications occur in 6% of patients with DMD. The MAPH technique as modified here is simple, quick, and accurate; furthermore, it is based on existing technology (i.e., hybridization, PCR, and electrophoresis) and should not require new equipment. Together, these features should allow easy implementation in routine diagnostic laboratories. Furthermore, the methodology should be applicable to any genetic disease, it should be easily expandable to cover >200 probes, and its characteristics should facilitate high-throughput screening.

[1]  L. Kunkel,et al.  Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction , 1990, Human Genetics.

[2]  B. McGillivray,et al.  Germinal mosaicism in Duchenne muscular dystrophy , 1988, Human Genetics.

[3]  L. Kunkel,et al.  Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing , 2001, BMC Genetics.

[4]  J. Mendell,et al.  Diagnosis of Duchenne dystrophy by enhanced detection of small mutations , 2001, Neurology.

[5]  F. Baas,et al.  Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. , 2001, Human molecular genetics.

[6]  R. Regan,et al.  Screening for subtelomeric chromosome abnormalities in children with idiopathic mental retardation using multiprobe telomeric FISH and the new MAPH telomeric assay , 2001, European Journal of Human Genetics.

[7]  Joe W. Gray,et al.  Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas , 2001, Nature Genetics.

[8]  A. Bosserhoff,et al.  Use of capillary electrophoresis for high throughput screening in biomedical applications. A minireview. , 2000, Combinatorial chemistry & high throughput screening.

[9]  C. Sismani,et al.  Measurement of locus copy number by hybridisation with amplifiable probes. , 2000, Nucleic acids research.

[10]  C. Mathew,et al.  High frequency of large intragenic deletions in the Fanconi anemia group A gene. , 1999, American journal of human genetics.

[11]  H. Sweeney,et al.  Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. , 1999, The Journal of clinical investigation.

[12]  P. Møller,et al.  MSH2 genomic deletions are a frequent cause of HNPCC , 1998, Nature Genetics.

[13]  Peter Devilee,et al.  BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.

[14]  C. Mathew,et al.  Dystrophin point mutation screening using a multiplexed protein truncation test. , 1997, Genetic testing.

[15]  J. Hata,et al.  Identification of carriers of Duchenne/Becker muscular dystrophy by a novel method based on detection of junction fragments in the dystrophin gene. , 1996, Journal of medical genetics.

[16]  J. D. den Dunnen,et al.  Splicing mutations in DMD/BMD detected by RT-PCR/PTT: detection of a 19AA insertion in the cysteine rich domain of dystrophin compatible with BMD. , 1996, Journal of medical genetics.

[17]  C. Mathew,et al.  Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis. , 1996, Journal of medical genetics.

[18]  E. Rappaport,et al.  Duchenne/Becker muscular dystrophy carrier detection using quantitative PCR and fluorescence-based strategies. , 1993, American journal of medical genetics.

[19]  L. Middleton,et al.  Detection of Duchenne and Becker muscular dystrophy carriers by quantitative multiplex polymerase chain reaction analysis , 1992, Neurology.

[20]  C. Mathew,et al.  A convenient multiplex PCR system for the detection of dystrophin gene deletions: a comparative analysis with cDNA hybridisation shows mistypings by both methods. , 1991, Journal of medical genetics.

[21]  L. Kunkel,et al.  Dystrophin is transcribed in brain from a distant upstream promoter. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. W. Thompson,et al.  Duplicational mutation at the Duchenne muscular dystrophy locus: its frequency, distribution, origin, and phenotypegenotype correlation. , 1990, American journal of human genetics.

[23]  C. van Broeckhoven,et al.  Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. , 1989, American journal of human genetics.

[24]  L. Kunkel,et al.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. , 1989, American journal of human genetics.

[25]  M. W. Thompson,et al.  Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene. , 1989, American journal of human genetics.

[26]  R A Gibbs,et al.  Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. , 1988, Nucleic acids research.

[27]  U. Francke,et al.  Intragenic deletions in 21 Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD) families studied with the dystrophin cDNA: location of breakpoints on HindIII and BglII exon-containing fragment maps, meiotic and mitotic origin of the mutations. , 1988, American journal of human genetics.

[28]  A. Monaco,et al.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. , 1988, Genomics.

[29]  M. W. Thompson,et al.  Genetics of Duchenne muscular dystrophy. , 1988, Annual review of genetics.

[30]  K. Davies,et al.  Preferential deletion of exons in Duchenne and Becker muscular dystrophies , 1987, Nature.

[31]  C. Broeckhoven,et al.  Germline mosaicism and Duchenne muscular dystrophy mutations , 1987, Nature.

[32]  M. Koenig,et al.  Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.